Compare EU & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | PRTC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 400.2M |
| IPO Year | 2011 | N/A |
| Metric | EU | PRTC |
|---|---|---|
| Price | $1.99 | $17.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 3.6K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,155,000.00 | N/A |
| Revenue This Year | $212.11 | N/A |
| Revenue Next Year | $29.88 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $14.50 |
| 52 Week High | $4.19 | $19.92 |
| Indicator | EU | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 58.79 |
| Support Level | $1.71 | $16.60 |
| Resistance Level | $2.17 | $18.20 |
| Average True Range (ATR) | 0.14 | 0.50 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 58.51 | 76.16 |
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.